NCT01748877CompletedPhase 2
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- NeurAxon Inc.
- Enrollment
- 188
- Locations
- 24
- Primary Endpoint
- Change from baseline to the last week of treatment in daily pain scores
Study Overview
Brief Summary
The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.
Detailed Description
NXN-462 is designed to target the nitric oxide synthase system (NOS), specifically the neuronal NOS (nNOS) isoform. By design, NXN-462 is a potent inhibitor of nNOS with good affinity, and has little or no affinity for a range of G protein-coupled receptors, ion channels, and enzymes. NXN-462 is being developed as an oral therapy for the treatment of neuropathic pain syndromes, including PHN. This drug design strategy provides a new therapeutic paradigm for the treatment of chronic neuropathic pain.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male, or a non-pregnant, non-lactating female 18 years or older
- •Have voluntarily provided written informed consent
- •able to speak, read, write, and understand English
- •clinical diagnosis of PHN for a minimum of 6 months
- •pain intensity score of ≥3 on a 0-10 Numerical Rating Scale (NRS) at the Screening Visit
- •generally in good health (other than PHN) at Screening
Exclusion Criteria
- •Are pregnant and/or lactating
- •Diagnosis of any chronic pain syndrome that would interfere with the assessment of PHN
- •evidence of multiple causes of neuropathic pain,e.g.lumbar radiculopathy in the lumbosacral area
- •Have had neuroablation or neurosurgical intervention for PHN
- •Have been taking opioid analgesics for >5 days/week
- •Have received nerve block or intrathecal analgesia within 6 weeks of the study
- •History of significant gastrointestinal disease, liver disease, renal disease, endocrine disease, or cardiovascular disease
- •clinically significant abnormal clinical laboratory test results or vital signs
- •Are immunocompromised or immunosuppressed for any reason
- •History of alcohol or other substance abuse (not including nicotine or tobacco) within 5 years
- •Significant psychiatric disorder which requires drug treatment (except depression or anxiety treated with Selective Serotonin Re-uptake Inhibitors)
- •Have received an investigational drug or have used an investigational device within 30 days of Screening.
- •Have previously been randomized to this study
Arms & Interventions
NXN-462
Experimental
capsule, 200 mg, bi.d. 28-days
Intervention: NXN-462 (Drug)
Placebo
Placebo Comparator
capsule, b.i.d. 28-days
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Change from baseline to the last week of treatment in daily pain scores
Time Frame: 4 weeks
Change from baseline to the last week of treatment in daily (24-hour recall) pain scores comparing NXN-462 with placebo
Secondary Outcomes
- percentage of responders(four weeks)
- Percentage of subjects with moderate or much improvement at the end of the Treatment Period, according to Patient Global Impression of Change(four weeks)
- average weekly change in pain score from baseline to the end of the Treatment Period(four weeks)
- Adverse events (AEs), vital signs, and clinical laboratory tests(six weeks)
- Analysis of percent change from baseline in daily pain score(four weeks)
- Change from baseline to the end of the Treatment Period in Pain Quality Assessment Scale score(four weeks)
- Rescue medication consumption(four weeks)
- Change from baseline to the end of the Treatment Period in Modified Brief Pain Inventory Short Form score, pain interference subscale(four weeks)
Investigators
Study Sites (24)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
A Study to Assess the Effect of the Natural Orange Extract in Individuals With Gastrointestinal DiscomfortGut HealthNCT06658717Vedic Lifesciences Pvt. Ltd.64
Completed
Phase 2
A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With AsthmaAsthmaNCT01551147Ono Pharma USA Inc25
Terminated
Phase 2
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)SCN8A Developmental and Epileptic Encephalopathy SyndromeNCT04873869Neurocrine Biosciences8
Completed
Phase 2
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFICBrain InjuriesNCT01366820Neuren Pharmaceuticals Limited261
Completed
Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum DepressionDepression, PostpartumPost-partum DepressionPostnatal DepressionPost-Natal DepressionPostpartum DepressionNCT06285916TWi Biotechnology, Inc.93